Peptide receptor radionuclide therapy of neuroendocrine tumors: Case series
نویسندگان
چکیده
منابع مشابه
Peptide receptor radionuclide therapy for advanced neuroendocrine tumors.
Peptide receptor radionuclide therapy (PRRT) consists of the systemic administration of a synthetic peptide, labeled with a suitable β-emitting radionuclide, able to irradiate tumors and their metastases via internalization through a specific receptor (usually somatostatin S2), over-expressed on the cell membrane. After almost 2 decades of experience, PRRT, with either (90)Y-octreotide or (177)...
متن کاملJoint guidance on peptide receptor radionuclide therapy in neuroendocrine tumors.
A practical guidance document on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumors is being published this month in the European Journal of Nuclear Medicine and Molecular Imaging (1). This document is the result of close collaboration among experts in the field of PRRNT from the International Atomic Energy Agency; the Radionuclide Therapy, Oncology, Dosimetry, and Radiophar...
متن کاملDevelopmental trends in targeted radionuclide therapy of neuroendocrine tumors
Neuroendocrine tumors (NETs) constitute a heterogeneous group of neoplasms including carcinoids, pancreatic neuroendocrine tumors, pituitary tumors, medullary thyroid carcinoma and phaeochromocytomas. The symptoms and the outcome of NETs differ considerably between patients depending on several factors. By labelling tracers with a radioisotope, the tracer acts as a ...
متن کاملDose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
UNLABELLED Peptide receptor radionuclide therapy (PRRT) is a promising treatment for patients with neuroendocrine tumors, giving rise to improved survival. Dosimetric calculations in relation to PRRT have been concentrated to normal organ dosimetry in order to limit side effects. However, the relation between the absorbed dose to the tumor and treatment response has so far not been established....
متن کاملPeptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues.
BACKGROUND Clinical experience with the radiolabeled somatostatin analogues 90Y-DOTATOC and, more recently, 177Lu-DOTATATE, is ongoing since more than a decade in few centers. Dosimetric studies demonstrated that 90Y-DOTATOC and 177Lu-DOTATATE are able to deliver high doses to somatostatin receptor sst2-expressing tumors and low doses to normal organs. RESULTS AND CONCLUSIONS Clinical studies...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Arhiv za onkologiju
سال: 2012
ISSN: 0354-7310,1450-9520
DOI: 10.2298/aoo1204143m